Unknown Analyst
Great. Afternoon, everybody. We’re pleased to have CytomX with us for the next fireside. Chris, I’m going to turn it over to you to make some — maybe make some opening comments, and then we can jump into it.
Chris Ogden
SVP, CFO & Secretary
Yes, hi, everyone, and thank you, Matthew, and the Morgan Stanley team for inviting us this year. Chris Ogden, Chief Financial Officer of CytomX. Just before starting, I will be making forward-looking statements, so I’ll refer you to our SEC filings for those disclosures. Just to start, CytomX is an oncology-focused company. And really, we refer to CytomX as the original masking company. We really invented the field of masked biologics. And what we mean by masking is we essentially have a technology where we can limit binding. We designed to limit binding of target biologic formats in healthy tissue, but activate those therapeutics preferentially in tumor cells.
So what that allows us to do from a design perspective is to really go after targets that other companies can’t drug. And so from our perspective, that’s led to clinical programs that are highly differentiated and are really enabled by our technology. We’ll talk more about those, but our 2 clinical programs: one is an ADC for colorectal cancer, the principal indication, and the other is a cytokine program focused in melanoma. So I think we’ll talk much more about those, but that’s really the focus of the company.